Danaher (NYSE:DHR) has signed
an agreement to sell its label-free biomolecular characterization,
chromatography hardware and resins, and microcarriers and particle
validation standards businesses to Sartorius AG (OTC:SARTF) for ~$750M.
The agreement was signed as a step towards
obtaining regulatory approval for its pending acquisition of the GE
Biopharma business.
The transaction is expected to be closed in Q1 2020.
https://seekingalpha.com/news/3507146-danaher-sell-certain-businesses-sartorius-750m
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.